Exploring the impact of baseline and on‐treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 <scp>BRIGHTE</scp> study
Multivariable analysis (MVA) identified several factors predictive of virologic response. No baseline factors were highly predictive of virologic failure at Weeks 96 or 192. Findings support the use of fostemsavir in diverse populations with MDR HIV-1.
Authors
- Qilong Liao (ORCID: https://orcid.org/0000-0002-0483-7559)
- José Castillo‐Mancilla (ORCID: https://orcid.org/0000-0003-1242-1745)
- Xuming Wang (ORCID: https://orcid.org/0000-0003-3590-562X)
- Fang Du (ORCID: https://orcid.org/0000-0002-7377-5259)
- Margaret Gartland (ORCID: https://orcid.org/0000-0002-1200-3706)
- Mark Krystal (ORCID: https://orcid.org/0000-0001-8905-2584)
- Bo Li (ORCID: https://orcid.org/0000-0002-9498-6389)
- Allan R. Tenorio (ORCID: https://orcid.org/0009-0007-2340-3389)
- Aimee Pierce
Institutions
- GlaxoSmithKline (United States) (US)
Publication Details
- Journal
- HIV Medicine
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1111/hiv.70154
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- ViiV Healthcare